![Figure 4 from Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate | Semantic Scholar Figure 4 from Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e73fcf29f06faf1b60a703b4d87ae7f2d4f3f8e9/6-Figure4-1.png)
Figure 4 from Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate | Semantic Scholar
![ONCOassist® | The go-to oncology app on X: "We are pleased to announce that the PSA doubling time calculator is live on ONCOassist! You can download ONCOassist or update through the below ONCOassist® | The go-to oncology app on X: "We are pleased to announce that the PSA doubling time calculator is live on ONCOassist! You can download ONCOassist or update through the below](https://pbs.twimg.com/media/Dyko_ngVYAA_rPe.png)
ONCOassist® | The go-to oncology app on X: "We are pleased to announce that the PSA doubling time calculator is live on ONCOassist! You can download ONCOassist or update through the below
![Implications of Prostate-Specific Antigen Doubling Time as Indicator of Failure after Surgery or Radiation Therapy for Prostate Cancer - ScienceDirect Implications of Prostate-Specific Antigen Doubling Time as Indicator of Failure after Surgery or Radiation Therapy for Prostate Cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0302283806013613-gr1.jpg)
Implications of Prostate-Specific Antigen Doubling Time as Indicator of Failure after Surgery or Radiation Therapy for Prostate Cancer - ScienceDirect
![MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure | Investigational New Drugs MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure | Investigational New Drugs](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs10637-008-9187-3/MediaObjects/10637_2008_9187_Fig1_HTML.gif)
MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure | Investigational New Drugs
![Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate | IntechOpen Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate | IntechOpen](https://cdnintech.com/media/chapter/41807/1512345123/media/image1.png)
Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate | IntechOpen
![Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate | IntechOpen Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate | IntechOpen](https://cdnintech.com/media/chapter/41807/1512345123/media/image5.png)
Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate | IntechOpen
![Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate | IntechOpen Describing Prostate Cancer Dynamics: Second Look at PSA- Doubling Time and PSA-Specific Growth Rate | IntechOpen](https://cdnintech.com/media/chapter/41807/1512345123/media/image11.png)